Cargando…

Non-Nodal CD5-Negative Mantle Cell Lymphoma with Secondary TP53 Deletion

Mantle cell lymphoma is a non-Hodgkin lymphoproliferative neoplasm with several clinical and morphologic variants linked, primarily, through genetic derangement of the cyclin D1 locus. Aberrant phenotypes have been described, though prognostic data in such cohorts are limited due to a paucity of cas...

Descripción completa

Detalles Bibliográficos
Autores principales:	McCall, Robert K., Pang, Changlee S., Pettenati, Mark J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7106885/ https://www.ncbi.nlm.nih.gov/pubmed/32257467 http://dx.doi.org/10.1155/2020/9185432

Ejemplares similares

Smudge cells in CD200(+), TP53 mutated leukemic mantle cell lymphoma
por: Jain, Preetesh, et al.
Publicado: (2022)

Mutant TP53 driving the Warburg Effect in Mantle Cell lymphoma
por: Kliebhan, Johannes, et al.
Publicado: (2022)

p53 is associated with high‐risk and pinpoints TP53 missense mutations in mantle cell lymphoma
por: Rodrigues, Joana M., et al.
Publicado: (2020)

Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations
por: Che, Yuxuan, et al.
Publicado: (2023)

An overlapping case of in situ mantle cell neoplasia and leukemic non-nodal mantle cell lymphoma
por: Matsuoka, Ryota, et al.
Publicado: (2020)

Autoimmune Gastritis With Progression of Leukemic Non-Nodal Mantle Cell Lymphoma
por: Saito, Makoto, et al.
Publicado: (2021)

The Leukemic Phase of ALK-Negative Anaplastic Large Cell Lymphoma Is Associated with CD7 Positivity, Complex Karyotype, TP53 Deletion, and a Poor Prognosis
por: Qiu, Lianqun, et al.
Publicado: (2021)

Repurposing auranofin to treat TP53-mutated or PTEN-deleted refractory B-cell lymphoma
por: Wang, Jeffrey, et al.
Publicado: (2019)

SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma – a Nordic Lymphoma Group study
por: Nordström, Lena, et al.
Publicado: (2014)

Deletions of 9p21 and TP53 in bladder cancer.
por: Park, W. S., et al.
Publicado: (1996)

CD5-negative Blastoid Variant Mantle Cell Lymphoma with Complex CCND1/IGH and MYC Aberrations
por: Seok, Yoonmi, et al.
Publicado: (2012)

Mantle cell lymphoma: involvement of nodal and extranodal sites in the head and neck, with multifocal oral lesions
por: Marcucci, Marcelo, et al.
Publicado: (2017)

TP-0903 Is Active in Preclinical Models of Acute Myeloid Leukemia with TP53 Mutation/Deletion
por: Eisenmann, Eric D., et al.
Publicado: (2022)

Genetic heterogeneity and prognostic impact of recurrent ANK2 and TP53 mutations in mantle cell lymphoma: a multi-centre cohort study
por: Jeong, Seri, et al.
Publicado: (2020)

Reappraisal of nodal Epstein‐Barr Virus‐negative cytotoxic T‐cell lymphoma: Identification of indolent CD5(+) diseases
por: Yamashita, Daisuke, et al.
Publicado: (2018)

Highly sensitive and specific in situ hybridization assay for quantification of SOX11 mRNA in mantle cell lymphoma reveals association of TP53 mutations with negative and low SOX11 expression
por: Federmann, Birgit, et al.
Publicado: (2020)

Concurrent TP53 and CDKN2A Gene Aberrations in Newly Diagnosed Mantle Cell Lymphoma Correlate with Chemoresistance and Call for Innovative Upfront Therapy
por: Malarikova, Diana, et al.
Publicado: (2020)

CD5-negative chronic lymphocytic leukemia/small lymphocytic lymphoma in a patient with gastrointestinal mantle cell lymphoma: an unusual case report
por: Chen, Dangui, et al.
Publicado: (2019)

Concurrent Presentation of Hairy Cell Leukemia and Mantle Cell Lymphoma (Leukemic Non-Nodal Variant): An Extremely Rare Composite Lymphoma
por: Soliman, Dina S., et al.
Publicado: (2022)

KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study
por: Ferrero, Simone, et al.
Publicado: (2020)

CD5-Negative Primary Mantle Cell Lymphoma Presenting with a Bilateral Conjunctival Mass: A Potential Diagnostic Pitfall
por: Zanelli, Magda, et al.
Publicado: (2023)

Prognostic significance of p53, Sox11, and Pax5 co-expression in mantle cell lymphoma
por: Jing, Caixia, et al.
Publicado: (2021)

Cutaneous Involvement as a First Sign of CD5(-) Blastoid Mantle Cell Lymphoma
por: Zekey, Emre, et al.
Publicado: (2023)

Clinical implications of cytogenetic heterogeneity in multiple myeloma patients with TP53 deletion
por: Hao, Suyang, et al.
Publicado: (2017)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

De Novo CD5 Negative Blastic Mantle Cell Lymphoma Presented with Massive Bone Marrow Necrosis without Adenopathy or Organomegaly
por: Elyamany, Ghaleb, et al.
Publicado: (2015)

Prognostic significance of CD117 expression and TP53 missense mutations in triple-negative breast cancer
por: Luo, Yanli, et al.
Publicado: (2018)

Impact of TP53 mutations in Triple Negative Breast Cancer
por: Mitri, Zahi I., et al.
Publicado: (2022)

Leukemic phase and CSF involvement of diffuse large B‐cell lymphoma with a complex karyotype including a TP53 deletion
por: Sinkoff, Jillian, et al.
Publicado: (2017)

Negative prognostic impact of low absolute CD4(+) T cell counts in peripheral blood in mantle cell lymphoma
por: Zhang, Xin‐Yu, et al.
Publicado: (2016)

Clinical significance of TP53 mutations in adult T‐cell leukemia/lymphoma
por: Sakamoto, Yuma, et al.
Publicado: (2021)

Targeting CD83 in mantle cell lymphoma with anti‐human CD83 antibody
por: Li, Ziduo, et al.
Publicado: (2020)

CD24 Is a Potential Immunotherapeutic Target for Mantle Cell Lymphoma
por: Freile, Jimena Álvarez, et al.
Publicado: (2022)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
por: Wang, Haiwei, et al.
Publicado: (2022)

Limited importance of the dominant-negative effect of TP53 missense mutations
por: Stoczynska-Fidelus, Ewelina, et al.
Publicado: (2011)

The contribution of CHEK2 to the TP53-negative Li-Fraumeni phenotype
por: Ruijs, Marielle WG, et al.
Publicado: (2009)

From uncertainty to pathogenicity: clinical and functional interrogation of a rare TP53 in-frame deletion
por: Quinn, Emily A., et al.
Publicado: (2019)

BMP7 Expression Correlates with Secondary Drug Resistance in Mantle Cell Lymphoma
por: Camara-Clayette, Valérie, et al.
Publicado: (2013)

Clinical characteristics and outcomes of primary versus secondary gastrointestinal mantle cell lymphoma
por: Castellino, Alessia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_n28si5fd951kvtqp3hc3dt3fgf